Abstract: The present invention relates to 2?-Alkynyl Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R1, R2, R3 and R4 are as defined herein. The present invention also relates to compositions comprising at least one 2?-Alkynyl Substituted Nucleoside Derivative, and methods of using the 2?-Alkynyl Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

Abstract: The present invention relates to compounds of formula I that are metallo-?-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with ?-lactam antibiotics for overcoming resistance.

Abstract: The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19 and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.

Abstract: The present invention relates to 2?-Alkynyl Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R1, R2, R3 and R4 are as defined herein. The present invention also relates to compositions comprising at least one 2?-Alkynyl Substituted Nucleoside Derivative, and methods of using the 2?-Alkynyl Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

Abstract: A method for modifying a non-woven fabric of chitosan fiber. The method includes: adding succinic anhydride to an industrial alcohol, ethanol, or acetone; controlling the mass ratio of succinic anhydride to the non-woven fabric at between 0.8 and 3.5; and stirring the resulting mixture until the succinic anhydride has dissolved to yield a succinic anhydride mixed solution; placing the succinic anhydride mixed solution in a constant temperature shaking bath; heating the succinic anhydride mixed solution; adding an HCl solution to the succinic anhydride mixed solution, and stirring evenly to yield a HCl mixed solution; immersing the non-woven fabric in the HCl mixed solution; dehydrating; immersing the non-woven fabric in ethanol or acetone; immersing the non-woven fabric in anhydrous ethanol or pure acetone; dehydrating; and air drying the non-woven fabric.

Abstract: The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19 and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.

Abstract: A quick brake assembly for a high-speed train, a high-speed car, aircraft, and a high-speed motorcycle. The quick brake assembly includes at least one lifting device providing on a bottom portion of a corresponding vehicle, at least one air braking device mounting on a predetermined position of the corresponding vehicle, and at least one nozzle braking device mounting on a bottom portion of the corresponding vehicle. The lifting device includes a braking member having a zigzag cross section. The nozzle baking device includes a nozzle having a flat nozzle head, wherein the nozzle braking device is arranged to store a predetermined amount of braking agent.

Abstract: The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19 and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.

Abstract: A method for modifying a non-woven fabric of chitosan fiber. The method includes: adding succinic anhydride to an industrial alcohol, ethanol, or acetone; controlling the mass ratio of succinic anhydride to the non-woven fabric at between 0.8 and 3.5; and stirring the resulting mixture until the succinic anhydride has dissolved to yield a succinic anhydride mixed solution; placing the succinic anhydride mixed solution in a constant temperature shaking bath; heating the succinic anhydride mixed solution; adding an HCl solution to the succinic anhydride mixed solution, and stirring evenly to yield a HCl mixed solution; immersing the non-woven fabric in the HCl mixed solution; dehydrating; immersing the non-woven fabric in ethanol or acetone; immersing the non-woven fabric in anhydrous ethanol or pure acetone; dehydrating; and air drying the non-woven fabric.

Abstract: The present invention relates to 2,3-Substituted Indole Derivatives, compositions comprising at least one 2,3-Substituted Indole Derivative, and methods of using the 2,3-Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.

Abstract: The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19 and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.

Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Abstract: The present invention relates to 2,3-Substituted Indole Derivatives, compositions comprising at least one 2,3-Substituted Indole Derivative, and methods of using the 2,3-Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.

Abstract: Inhomogeneous concentrated polymer network with approximately 90° twisted nematic liquid crystal (TN-LC) is used for fabricating lens and prisms. For forming a positive lens, the approximately 90° TN-LC polymer network concentration can gradually decrease from the center to the side edges. For forming a negative lens, the approximately 90° TN-LC polymer network concentration can gradually increase from the center to the side edges. The lens can be created by ultra violet (UV) light exposure to patterned photo masks. The lens can be tuned by applying voltage above the threshold voltage to the polymer network. The inhomogeneous 90° TN-LC polymer network can also be used in Fresnel lens and prisms. Applications of the invention can be used for micro lens, array, optical communication, micro-optics, adaptive optics and beam steering.

Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.